Cetuximab as a Component of Multimodality Treatment of High-Risk Cutaneous Squamous Cell Carcinoma: A Retrospective Analysis From a Single Tertiary Academic Medical Center-Reference-Cited by-同舟云学术

Cetuximab as a Component of Multimodality Treatment of High-Risk Cutaneous Squamous Cell Carcinoma: A Retrospective Analysis From a Single Tertiary Academic Medical Center

Published:2019-02 Issue:2 Volume:45 Page:254-267
ISSN:1076-0512
Container-title:Dermatologic Surgery
language:en
Short-container-title:DS

Author:

Trodello Cameron,Higgins Shauna,Ahadiat Omeed,Ragab Omar,In Gino,Hawkins Makenzie,Wysong Ashley

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Dermatology,General Medicine,Surgery

Reference33 articles.

1. A systematic review of worldwide incidence of nonmelanoma skin cancer;Lomas;Br J Dermatol,2012

2. Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the U.S. population, 2012;Rogers;JAMA Dermatol,2015

3. Cutaneous squamous-cell carcinoma;Alam;N Engl J Med,2001

4. Evaluation of AJCC tumor staging for cutaneous squamous cell carcinoma and a proposed alternative tumor staging system;Jambusaria-Pahlajani;JAMA Dermatol,2013

5. Management of high-risk cutaneous squamous cell carcinoma;Jennings;J Clin Aesthet Dermatol,2010

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Revolutionizing non‐melanoma skin cancer treatment: Receptor tyrosine kinase inhibitors take the stage;Journal of Cosmetic Dermatology;2024-05-29

2. Cutaneous Squamous Cell Carcinoma: An Updated Review;Cancers;2024-05-08

3. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment–Update 2023;European Journal of Cancer;2023-11

4. Squamous-Cell Carcinoma of the Skin;New England Journal of Medicine;2023-06-15

5. Sequencing of Cutaneous Squamous Cell Carcinoma Primary Tumors and Patient-Matched Metastases Reveals ALK as a Potential Driver in Metastases and Low Mutational Concordance in Immunocompromised Patients;JID Innovations;2022-07